Karo Bio Articles
Karo Bio drops eprotirome and split up plans
15 February 2012
Karo Bio skyrockets on deal with Pfizer
28 December 2011
Karo Bio to spin off preclinical development
26 October 2011
Showing 1-5 of 5 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
